Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study)

SIMPLE SUMMARY: We conducted the Neo-LaTH study in which patients with HER2-positive breast cancer were randomized to different lengths of neoadjuvant induction anti-HER2 therapy with lapatinib and trastuzumab followed by weekly paclitaxel plus anti-HER2 therapy, and in estrogen receptor-positive pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Tokunaga, Eriko, Masuda, Norikazu, Yamamoto, Naohito, Iwata, Hiroji, Bando, Hiroko, Aruga, Tomoyuki, Ohtani, Shoichiro, Fujisawa, Tomomi, Takano, Toshimi, Inoue, Kenichi, Suganuma, Nobuyasu, Takada, Masahiro, Aogi, Kenjiro, Sakurai, Kenichi, Shigematsu, Hideo, Kuroi, Katsumasa, Haga, Hironori, Ohno, Shinji, Morita, Satoshi, Toi, Masakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394774/
https://www.ncbi.nlm.nih.gov/pubmed/34439165
http://dx.doi.org/10.3390/cancers13164008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394774/
https://www.ncbi.nlm.nih.gov/pubmed/34439165
http://dx.doi.org/10.3390/cancers13164008

Ejemplares similares